Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab in sporadic inclusion body myositis (phase IIb/III, 6MWD at 52 weeks)
2013-000705-23Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in inclusion body myositis (IBM) comparing Bimagrumab intravenous with Placebo intravenous (2 arms). Primary endpoint: Change from baseline in 6-minute walking distance test (6MWD) at week 52. Started Dec 2013; status: completed.
02
Drugs
bimagrumab
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on 2013-000705-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000705-23.